Industry news
Medivation rejects Sanofi offer
Medivation, Inc. announced that its Board of Directors, after consultation with its financial and legal advisers, unanimously determined that the unsolicited proposal from Sanofi to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the company and its stockholders.